Evidence map›Paper›PMID 41275281›Full record

ArticleJournal of nanobiotechnology2025

A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer.

Yuanfeng Zhang, Enguang Yang, Xinyu Zhang, Yibo Shi, Guangrui Fan, Yuhan Wang, Junqiang Tian, Hanzhang Wang, Zhilong Dong, Yingru Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuanfeng Zhang *Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Enguang Yang *Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Xinyu Zhang *Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Yibo ShiInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Guangrui FanRobotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, P. R. China.
Yuhan WangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Junqiang TianInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Hanzhang WangDepartment of Pathology and Laboratory Medicine, The Legorreta Cancer Center at Brown University, The Warren Albert Medical School of Brown University, Lifespan Academic Medical Center, Providence, RI, USA.
Zhilong DongInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Yingru WangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.
Liang ChengDepartment of Pathology and Laboratory Medicine, The Legorreta Cancer Center at Brown University, The Warren Albert Medical School of Brown University, Lifespan Academic Medical Center, Providence, RI, USA.
Zhiwen ZhaoState Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, Lanzhou University, Lanzhou, 730000, P.R. China.
Yonghai ZhangDepartment of Urology, Shantou Central Hospital, Shantou Key Laboratory of Basic and Translational Research of Malignant Tumor, Shantou, 515031, P. R. China.
Baodui WangState Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, Lanzhou University, Lanzhou, 730000, P.R. China.
Zhiping WangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China. wangzplzu@163.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515220184Gansu Provincial Joint Foundation Program 23JRRA1511Key Research and Development Program of Gansu Province 23YFFA0007Major Program of Gansu Province 24ZDFA002National Natural Science Foundation of China 82372685Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine 20262049
6 · The paper itself

Abstract

backgroundJuglone, a natural naphthoquinone compound, exhibits potent anticancer activity but faces clinical limitations due to poor solubility, low bioavailability, and systemic toxicity. While tumor microenvironment-responsive drug activation strategies offer a promising solution, achieving precise spatial control over the conversion of non-toxic precursors into cytotoxic agents remains a significant challenge.

methodsWe developed DHN@Pt/PtMBCPsNSs, a platinum (Pt)-methylene blue (MB)- based nanoscale sonosensitizer, to enable ultrasound-triggered on-demand juglone synthesis within tumors. The system was evaluated in bladder cancer models including cell lines, patient-derived organoids (PDOs) and patient-derived tumor xenograft (PDX) models, assessing tumor uptake, intracellular distribution, hypoxia modulation ("H

resultsDHN@Pt/PtMBCPsNSs were internalized by UMUC-3 and T24 cells and primarily accumulated within the mitochondrial compartments. The platinum-based components catalytically exhausted GSH via redox cycling. DHN@Pt/PtMBCPsNSs triggered the production of O

conclusionsAs a novel sonosensitizer and pyroptosis inducer, DHN@Pt/PtMBCPsNSs achieve a precise synergistic effect of chemotherapy and sonodynamic therapy within cells, while minimizing adverse effects on normal cells and overcoming the limitations associated with natural chemotherapeutic agents. This approach may advance clinical translation of natural anticancer agents.

Indexed as

Antineoplastic AgentsCaspase 3NaphthoquinonesPyroptosisUrinary Bladder NeoplasmsAnimalsApoptosisCell Line, TumorGlutathioneHumansMiceMice, NudeTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic AgentsCaspase 3GlutathionejugloneNaphthoquinonesBladder cancerJuglonePyroptosisSonodynamic therapySonosensitizer

Identifiers

PMID41275281
PMCPMC12752224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.